Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.

Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.


October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess patients’ risk during pre-transcatheter aortic valve replacement (TAVR) workup and post-procedural surveillance. This is according to a new study published in the American Roentgen Ray Society (ARRS) American Journal of Roentgenology (AJR).[1]

“LAEF derived from preprocedural cardiac CTA independently predicts mortality in patients with severe aortic stenosis undergoing TAVR,” concluded corresponding author Joseph Schoepf, M.D., from the Medical University of South Carolina’s Heart and Vascular Center.

Aortic stenosis (AS) is an obstructive valvular disorder associated with changes in the left ventricle (LV) and left atrium (LA). Chronically elevated LV pressures lead to LV myocardial hypertrophy and fibrosis, which consequently lead to LA enlargement and remodeling to maintain adequate filling of the LV. These changes in the LA function can be used as an early indicator of atrial remodeling and can be demonstrated by reduced LAEF, and increased maximum (LAVmax) and minimum (LAVmin) LA volume. The authors of the study said parameters of LA function are most commonly assessed using transthoracic echocardiography (TTE), but can also be evaluated with cardiac MRI and cardiac CCTA. In patients with severe AS undergoing TAVR, LA dilatation assessed by TTE is associated with poor outcome, which raised the question if CTA could be used to assess TAVR patients.

CT is already required for preprocedural workup of patients undergoing TAVR and provides not only information on the arterial access route, but also anatomic and morphologic assessment of the aortic valve for annular prosthesis sizing, positioning of the valve and determination of risk of annular injury or coronary occlusion. Information on preprocedural CTA can also provide information on volumes and function of the LA with appropriate post-processing and this study looked at whether the data could be leveraged to predict outcomes in patients undergoing TAVR.

Schoepf and colleagues’ retrospective single-center study included 175 patients with severe aortic stenosis (92 male, 83 female; median age, 79 years) who underwent cardiac CTA for clinical pre-TAVR assessment. Maximum and minimum left atrium volumes were calculated using biplane area-length measurements, and the values were indexed to body surface area: LAVImax and LAVImin, respectively.

In their sample, a reduced LAEF independently predicted all-cause mortality within 24 months post-procedure (hazard ratio 0.97 [0.94–0.99]; p=.02). Moreover, when incorporating LAEF, the c-index of the Society of Thoracic Surgeons Predicted Risk of Mortality significantly increased from 0.64 to 0.70.

Acknowledging that atrial parameters are more commonly assessed using transthoracic echocardiography, both atrial volume and atrial function can be reliably assessed using cardiac CTA, “which now represents the gold standard for preprocedural planning in patients undergoing TAVR,” the authors of this AJR article added.

For more information: arrs.org

Find more cardiac CT content

 

Reference:

1. Gilberto J. Aquino, Josua A. Decker, U. Joseph Schoepf, et al. Utility of Functional and Volumetric Left Atrial Parameters Derived From Preprocedural Cardiac CTA in Predicting Mortality After Transcatheter Aortic Valve Replacement. AJR. Oct 13 [published online]. Accepted manuscript. doi:10.2214/AJR.21.26775.


Related Content

News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
News | Computed Tomography (CT)

SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...

Time August 06, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
Subscribe Now